Pfizer reveals delays across the board for its clinical gene therapy programs
At JP Morgan 2020, a year after taking the reins at Pfizer, Albert Bourla claimed the company was poised to become a leader in gene therapy. He’s since thrown hundreds of millions of dollars at those plans, including a $630 million deal just last month for two of Voyager’s AAVs.
Now, it appears Phase III readouts are further away than Bourla had hoped.
Setbacks have resulted in delays across all three of Pfizer’s clinical gene therapy programs, the company revealed in its Q3 results on Tuesday — including one trial which was paused over safety concerns.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.